Chipscreen(SH:688321) Zheng Quan Ri Bao·2025-10-30 23:44Core Viewpoint - The company reported a significant increase in revenue for the first nine months of 2025, driven primarily by the sales of its products, with notable growth in specific product lines [3]. Financial Performance - The company's revenue for the period from January to September 2025 grew by 40.12%, attributed to increased sales of its products, particularly: - Sales revenue from Sidabamine increased by 18.76% - Sales revenue from Siglecatin surged by 136.13% [3]. Audit Status - The financial statements for the third quarter were not audited [3][6]. Shareholder Information - There were no changes reported in the top ten shareholders or any significant movements in shareholding due to stock lending activities [5][6]. Other Important Information - The company confirmed that the financial report is accurate and complete, with no significant omissions or misleading statements [2][4].